Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model

Background Combining allergen(s) with an adjuvant is a strategy to improve the efficacy and safety of allergen‐specific immunotherapy. Here, we aimed at investigating the adjuvant effects of polyadenylic–polyuridylic acid (poly(A:U)), a TLR3 agonist, and R848 (resiquimod), a TLR7 agonist, in epicuta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Allergy (Copenhagen) 2014-03, Vol.69 (3), p.328-337
Hauptverfasser:	Siebeneicher, S., Reuter, S., Krause, M., Wangorsch, A., Maxeiner, J., Wolfheimer, S., Schülke, S., Naito, S., Heinz, A., Taube, C., Vieths, S., Scheurer, S., Toda, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	adjuvant Administration, Cutaneous Allergies Animals Antigens, Plant - administration & dosage Antigens, Plant - immunology Asthma Asthma - immunology Asthma - pathology Asthma - therapy birch pollen allergy Desensitization, Immunologic Disease Models, Animal epicutaneous immunization Female Imidazoles - administration & dosage Immunization Immunoglobulin E - immunology Immunoglobulin G - immunology Immunotherapy Mice Premedication R848 Recombinant Proteins - administration & dosage Recombinant Proteins - immunology Th1 Cells - immunology Th1 Cells - metabolism TLR7 agonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!